ASH 2025 – BeOne assuages sonrotoclax safety concerns
Of 15 treatment-emergent adverse events, only one was deemed related to therapy.
ASH 2025 – BeOne pulls away from Nurix
On efficacy, at least, BeOne’s BTK degrader shows an edge.
NACLC 2025 – BioNTech gets a gotistobart boost
The first stage of Preserve-003 shows a survival benefit in post-PD-(L)1 lung cancer – with caveats.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
ESMO Asia 2025 – Oric’s first-line gamble
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
Black Diamond picks brain cancer for silevertinib
Though lung cancer looks promising a partner is now needed.
ADC slides on latest Zynlonta update
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
Imvax’s brain fail
But the group still hopes to get IGV-001 approved based on overall survival data.
